Overview

A Prospective, Open, Multicenter Clinical Trial of Eltrombopag Combined With Diacerein in Eltrombopag-inefficient or Relapsed ITP

Status:
Completed

Trial end date:
2020-11-01

Target enrollment:

Participant gender:

Summary

Eltrombopag is an oral thrombopoietin receptor agonist that has been licensed for use as second line therapy in ITP patients. Diacerein is a slow-acting medicine of the class anthraquinone used to treat joint diseases such as osteoarthritis. The project was undertaking by Qilu Hospital of Shandong University and other 5 well-known hospitals in China. In order to report the efficacy and safety of eltrombopag combined with diacerein in the management of eltrombopag combined with diacerein.

Phase:

Phase 2

Details

Lead Sponsor:

Shandong University

Collaborators:

Anhui Medical University
Shenzhen Second People's Hospital
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
The First Affiliated Hospital of Dalian Medical University
Zhejiang Provincial Hospital of TCM

Treatments:

Diacetylrhein